3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
14
Fallopian Tube Neoplasms
13
Carcinoma, Ovarian Epithelial
7
Prostatic Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Leiomyosarcoma
1
Glioblastoma
1
Genital Neoplasms, Male
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
8
Oxaliplatin
7
Surveys and Questionnaires
5
Methods
5
Early Intervention, Educational
5
Cyclophosphamide
5
Cisplatin
5
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Gemcitabine
4
Fluorouracil
4
Carboplatin
4
veliparib
3
aldesleukin
3
Trastuzumab
3
Specimen Handling
3
Nivolumab
3
Diathermy
3
Cytoreduction Surgical Procedures
3
sargramostim
2
entinostat
2
cemiplimab
2
cediranib
2
X-Rays
2
Therapeutics
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Metformin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
rucaparib
×
Gynecologic
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts